Cargando…

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1

BACKGROUND AND OBJECTIVE: Side effects of irinotecan treatment can be dose limiting and may impair quality of life. In this study, we investigated the correlation between single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in the irinotecan metabolism and transport, outside UGT...

Descripción completa

Detalles Bibliográficos
Autores principales:	de With, Mirjam, van Doorn, Leni, Kloet, Esmay, van Veggel, Anne, Matic, Maja, de Neijs, Micha J., Oomen - de Hoop, Esther, van Meerten, Esther, van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582127/ https://www.ncbi.nlm.nih.gov/pubmed/37715926 http://dx.doi.org/10.1007/s40262-023-01279-7

Ejemplares similares

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
por: Agema, Bram C., et al.
Publicado: (2020)

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients
por: de Man, Femke M., et al.
Publicado: (2019)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Clinical Application of Pharmacogenetics: Where are We Now?
por: van Schaik, Ron HN
Publicado: (2014)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners
por: van der Drift, Denise, et al.
Publicado: (2023)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
por: Kuip, Evelien J. M., et al.
Publicado: (2018)

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
por: de Man, Femke M., et al.
Publicado: (2019)

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study
por: van Dorst, Daan C. H., et al.
Publicado: (2022)

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
por: van Doorn, Leni, et al.
Publicado: (2022)

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
por: van Doorn, Leni, et al.
Publicado: (2021)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
por: van Schaik, Ron H. N., et al.
Publicado: (2020)

Call for Manuscript Submissions for a Thematic eJIFCC Issue on “Pharmacogenetics and Personalized Therapy”
por: van Schaik, Ron H. N., et al.
Publicado: (2022)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
por: van Doorn, Leni, et al.
Publicado: (2021)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl
por: Kuip, Evelien J.M., et al.
Publicado: (2018)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review
por: Yalçin, Nadir, et al.
Publicado: (2022)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer
por: Kuip, Evelien J. M., et al.
Publicado: (2018)

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_g1p88dg9spofmpuap6imhsbrdv